All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Gilead Sciences Inc. has bought the privately owned U.K. biotech Mirobio Ltd., paying $405 million for the Oxford-based firm and its checkpoint agonists to treat autoimmune diseases. Foster City, Calif.-based Gilead will gain Mirobio’s discovery platform and entire portfolio of immune inhibitory receptor agonists.